Evidence map›Paper›PMID 30710387›Full record

ArticleBritish journal of clinical pharmacology2019

Pharmacokinetics of ticarcillin-clavulanate in premature infants.

Kevin M Watt, Christoph P Hornik, Stephen J Balevic, Gratias Mundakel, C Michael Cotten, Barrie Harper, Daniel K Benjamin, Ravinder Anand, Matthew Laughon, P Brian Smith and 2 more

Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase IMulticenter Study
In one paragraph

Article in British journal of clinical pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01728363 (Pharmacokinetics of Antistaphylococcal Antibiotics in Infants), which is not on this map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01728363 phase1completednot on this map

Pharmacokinetics of Antistaphylococcal Antibiotics in Infants

TypeinterventionalSponsorPhillip Brian SmithRan2013 to 2015Enrolled63ConditionsSystemic InfectionArmsAntibiotic
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Pharmacokinetics of ticarcillin-clavulanate in premature infants.British journal of clinical pharmacology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Kevin M WattDuke University Medical Center, Durham, NC, USA.ORCID 0000-0002-5975-5091
Christoph P HornikDuke University Medical Center, Durham, NC, USA.
Stephen J BalevicDuke University Medical Center, Durham, NC, USA.
Gratias MundakelKings County Hospital Center, Brooklyn, NY, USA.
C Michael CottenDuke University Medical Center, Durham, NC, USA.
Barrie HarperDuke Clinical Research Institute, Durham, NC, USA.
Daniel K BenjaminDuke University Medical Center, Durham, NC, USA.
Ravinder AnandEmmes Corporation, Rockville, MD, USA.
Matthew LaughonUniversity of North Carolina Medical Center, Chapel Hill, NC, USA.
P Brian SmithDuke University Medical Center, Durham, NC, USA.
Michael Cohen-WolkowiezDuke University Medical Center, Durham, NC, USA.
Best Pharmaceuticals for Children Act - Pediatric Trials Network Steering Committee
Clinical Research Institute · USDuke Medical Center · USEmmes (United States) · USKings County Hospital Center · USUniversity of North Carolina at Chapel Hill · US

Funding

Physiologically-Based Pharmacokinetic Approach to Determine Dosing on Extracorporeal Life SupportR01HD097775 · NICHD · UNIVERSITY OF UTAH · PI WATT, KEVIN M · 2019 to 2023
$2.7M
Physiologically Based Pharmacokinetics in Critically Ill ChildrenK23HD075891 · NICHD · DUKE UNIVERSITY · PI WATT, KEVIN M · 2014 to 2018
$638k
NICHD NIH HHS HHSN275201000003INICHD NIH HHS K23 HD075891NICHD NIH HHS R01 HD097775
6 · The paper itself

Abstract

Ticarcillin-clavulanate covers a broad spectrum of pathogens that are common in premature infants. In infants <30 weeks gestational age, pharmacokinetic data to guide ticarcillin-clavulanate dosing are lacking. We enrolled 15 premature infants <30 weeks gestational age, determined pharmacokinetic parameters, and performed dosing simulations to determine optimal dosing for ticarcillin-clavulanate. The infants had a median (range) postnatal age (PNA) of 18 days (6-44 days) and gestational age of 25 weeks (23-28 weeks). Clearance was lower in infants with a PNA <14 days (0.050 L/kg/h [range 0.043-0.075]) compared with a PNA ≥14-45 days (0.078 L/kg/h [0.047-0.100]), consistent with maturation of renal function. Dosing simulations determined that ticarcillin 75 mg/kg q12h (PNA <14 days) or q8h (PNA ≥ 14-45 days) achieved the target exposure for organisms with a minimum inhibitory concentration ≤16 μ/mL in >90% of simulated infants. For highly resistant organisms (minimum inhibitory concentration 32 μg/mL), increased dosing frequency or extended infusion are necessary.

Indexed as

beta-Lactamase InhibitorsClavulanic AcidsComputer SimulationDose-Response Relationship, DrugDrug Dosage CalculationsFemaleHumansInfant, Extremely PrematureInfant, NewbornMaleMicrobial Sensitivity TestsModels, BiologicalProspective StudiesStaphylococcal InfectionsStaphylococcusTicarcillinbeta-Lactamase InhibitorsClavulanic AcidsTicarcillinticarcillin-clavulanic acidclavulanateinfantspharmacokineticsprematureticarcillin

Identifiers

PMID30710387
PMCPMC6475694
OpenAlexW2912809048

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.